Health Care/Hospital
Skyline Therapeutics' Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
BOSTON and SHANGHAI, Sept. 3, 2024 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) fo...
2024-09-03 18:00
1125
QingSong Health Chairman Speaks at Global Ethics Forum in Geneva: Advancing Ethical Leadership in Healthcare
GENEVA, Sept. 3, 2024 /PRNewswire/ -- At the Global Ethics Forum, a leading platform that convenes stakeholders from various sectors to discuss peace, sustainability, and ethical leadership, the Chairman of QingSong Health,China's premier healthcare solutions technology platform, delivered a comp...
2024-09-03 16:27
1320
GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA
* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" * Improves efficacy compared to existing treatment for kidney function, vascular disease, and peripheral nerve disorders YONGIN, South Korea, Sept. 3, 2024 /PR...
2024-09-03 15:59
1252
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease
NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase2b study for Dercum's disease (CBL-0202 DD Phase2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD study i...
2024-09-03 15:18
1238
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase ...
2024-09-02 20:24
1661
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted theChina rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasi...
2024-08-30 19:34
5728
Breaking News | Sanyou Bio Launches Comprehensive Monkeypox Product Line
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines. This product line features 65 items ...
2024-08-30 18:00
2640
/DISREGARD RELEASE: Celltrion USA/
We are advised by Celltrion USA that journalists and other readers should disregard the news release, CelltrionUSA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit ...
2024-08-30 08:35
1915
Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London
PISCATAWAY, N.J., Aug. 29, 2024 /PRNewswire/ -- The cell and gene therapy (CGT) industry has witnessed remarkable growth in recent years. According to an analysis by RSM US LLP, CGT therapies accounted for 10% of all FDA-approved drugs last year, with the number of approvals anticipated to contin...
2024-08-29 21:51
1383
CARsgen® Announces 2024 Interim Results
SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced its 2024 Interim Results. Business Highlights * Zevor-cel was...
2024-08-29 20:50
3548
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
BOSTON, Aug. 29, 2024 /PRNewswire/ -- In August 2024, Medicilon USA Corp (Medicilon) officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone heralds Medicilon's continu...
2024-08-29 20:30
1296
So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq
BEIJING, Aug. 29, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced it has received a notificatio...
2024-08-29 17:30
2880
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
2024 Interim Result Highlights (For the six months ended June 30, 2024) * Company published the efficacy and safety data of Cohort-G of TranStar102 study for osemitamab (TST001), plus checkpoint inhibitor and CAPOX as the first-line treatment of patients with locally advanced or metastatic G/GE...
2024-08-29 14:31
2754
111, Inc. Announces Second Quarter 2024 Unaudited Financial Results
* Maintained Operational Profitability for the Second Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY * Held Positive Operating Cash Flow for Two Consecutive Quarters SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company"...
2024-08-29 14:00
2888
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
* Approval of ivonescimab for 2L+ EGFRm NSCL; HARMONi-A is the only phase III study that demonstrates significant benefit across all subgroups for PFS, and is also the only study to achieve the primary endpoint while showing a positive trend in OS benefit; HARMONi-A study presented in an oral p...
2024-08-29 04:20
2413
Jenscare, with innovative TTVR, releases 2024H1 interim results
BEIJING, Aug. 28, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, released interim results for 2024H1 endedJune 30, 2024...
2024-08-28 21:00
2323
Bloomage Showcases Key Bioactive Substances at CPHI and HI Korea
SEOUL, South Korea, Aug. 28, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substances, showcased its new products releasing inSouth Korea at CPHI and HI Korea 2024, two of the largest exhibitions related to health and functional foods, held betweenAug. 27 t...
2024-08-28 21:00
1659
Sasakawa Leprosy Initiative Collaborates with Miss Supranational 2024 for Leprosy Awareness Campaign in South Sulawesi, Indonesia
TOKYO, Aug. 28, 2024 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative (SLI) recently conducted a series of leprosy awareness activities in South Sulawesi,Indonesia, in partnership with Miss Supranational 2024 crown holder, Miss Harashta Haifa Zahra. The activities were carried out i...
2024-08-28 19:00
1852
Tigermed Reports 2024 Interim Results
HANGZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
2024-08-28 18:26
2011
Fosun Pharma Announces 2024 Interim Results
Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its o...
2024-08-28 18:10
2010
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 337 media titles]
2025-01-18 03:30
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 311 media titles]
2025-01-22 15:38
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 311 media titles]
2025-01-18 17:00
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
12380
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
11584
Boosting Yeast Protein Production to Meet the Growing Global Demand for Alternative Proteins
2025-01-17 22:46
10223
Dongying's vibrant Spring Festival awaits visitors
2025-01-17 21:46
10085